| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_259045c6eba6e2c5d338b84e0a88b571
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6ec38905d57b9fda6d35ea26e720f958 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2603-74 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C235-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D307-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C231-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-167
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-341 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C231-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D307-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C235-24 |
| filingDate |
2015-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a8598bb2f58bd7d9412a28ae9df1640a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_670fe1d5151a7082d18211ec82be78e5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_78598b822e5f041f28aff81ed3111f35
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c8a3a69936808b382c2538d7071e78a1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_06e5f4c6ef9436fc95a8627bf9c68499
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_708b506e702fd61c9f95209705f74a63 |
| publicationDate |
2015-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2015259312-A1 |
| titleOfInvention |
Novel disubstituted adamantyl derivative or pharmaceutically acceptable salt thereof, production method for same, and pharmaceutical composition for suppressing cancer metastasis comprising same as active ingredient |
| abstract |
The present invention relates to a novel disubstituted adamantyl derivative or the pharmaceutically acceptable salts thereof, a method for preparing the same, and a pharmaceutical anticancer or antimetastasis composition comprising the same as an active ingredient. The disubstituted adamantyl derivative of the present invention suppressed accumulation of HIF-1α, inhibiting the expression of the metastasis related protein Twist dose-dependently. Thus, the disubstituted adamantyl derivative of the invention is effective in inhibiting the expressions of the metastasis related proteins, β-catenin and RohA, and the EMT related genes such as MMP2 and MMP9, without cytotoxicity. Therefore, the disubstituted adamantyl derivative or the pharmaceutically acceptable salts thereof of the invention can be efficiently used as a pharmaceutical anticancer or antimetastasis composition. |
| priorityDate |
2012-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |